| Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell … E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ... Blood, The Journal of the American Society of Hematology 115 (22), 4393-4402, 2010 | 1106 | 2010 |
| Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial D Catovsky, S Richards, E Matutes, D Oscier, MJS Dyer, RF Bezares, ... The Lancet 370 (9583), 230-239, 2007 | 943 | 2007 |
| Bcl10 is involved in t (1; 14)(p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types TG Willis, DM Jadayel, MQ Du, H Peng, AR Perry, M Abdul-Rauf, H Price, ... Cell 96 (1), 35-45, 1999 | 832 | 1999 |
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ... Journal of Clinical Oncology 28 (10), 1749-1755, 2010 | 805 | 2010 |
| Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival NA Johnson, KJ Savage, O Ludkovski, S Ben-Neriah, R Woods, C Steidl, ... Blood, The Journal of the American Society of Hematology 114 (11), 2273-2279, 2009 | 744 | 2009 |
| Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H G Hale, MR Clark, R Marcus, G Winter, MJS Dyer, JM Phillips, ... The Lancet 332 (8625), 1394-1399, 1988 | 735 | 1988 |
| Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells C Bellodi, MR Lidonnici, A Hamilton, GV Helgason, AR Soliera, ... The Journal of clinical investigation 119 (5), 1109-1123, 2009 | 701 | 2009 |
| Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. A Osterborg, MJ Dyer, D Bunjes, GA Pangalis, Y Bastion, D Catovsky, ... Journal of Clinical Oncology 15 (4), 1567-1574, 1997 | 673 | 1997 |
| Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia LJ Russell, M Capasso, I Vater, T Akasaka, OA Bernard, MJ Calasanz, ... Blood, The Journal of the American Society of Hematology 114 (13), 2688-2698, 2009 | 611 | 2009 |
| Ultrastructural localization of bcl-2 protein. P Monaghan, D Robertson, TA Amos, MJ Dyer, DY Mason, MF Greaves Journal of Histochemistry & Cytochemistry 40 (12), 1819-1825, 1992 | 520 | 1992 |
| Bcl-2 inhibitors: small molecules with a big impact on cancer therapy M Vogler, D Dinsdale, MJS Dyer, GM Cohen Cell Death & Differentiation 16 (3), 360-367, 2009 | 479 | 2009 |
| Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype MJ Dyer, G Hale, FG Hayhoe, H Waldmann | 468 | 1989 |
| A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia MC Di Bernardo, D Crowther-Swanepoel, P Broderick, E Webb, G Sellick, ... Nature genetics 40 (10), 1204-1210, 2008 | 466 | 2008 |
| The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies TG Willis, MJS Dyer Blood, The Journal of the American Society of Hematology 96 (3), 808-822, 2000 | 436 | 2000 |
| Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia M Vogler, M Butterworth, A Majid, RJ Walewska, XM Sun, MJS Dyer, ... Blood, The Journal of the American Society of Hematology 113 (18), 4403-4413, 2009 | 401 | 2009 |
| High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H CE Dearden, E Matutes, B Cazin, GE Tjønnfjord, A Parreira, B Nomdedeu, ... Blood, The Journal of the American Society of Hematology 98 (6), 1721-1726, 2001 | 396 | 2001 |
| The CAMPATH‐1 antigen (CDw52) G Hale, MQ Xia, HP Tighe, MJS Dyer, H Waldmann Tissue antigens 35 (3), 118-127, 1990 | 396 | 1990 |
| The BCL11 gene family: involvement of BCL11A in lymphoid malignancies E Satterwhite, T Sonoki, TG Willis, L Harder, R Nowak, EL Arriola, H Liu, ... Blood, The Journal of the American Society of Hematology 98 (12), 3413-3420, 2001 | 394 | 2001 |
| The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo VJ Weston, CE Oldreive, A Skowronska, DG Oscier, G Pratt, MJS Dyer, ... Blood, The Journal of the American Society of Hematology 116 (22), 4578-4587, 2010 | 351 | 2010 |
| Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia … B Austen, A Skowronska, C Baker, JE Powell, A Gardiner, D Oscier, ... Journal of Clinical Oncology 25 (34), 5448-5457, 2007 | 350 | 2007 |
Jose A Martinez-Climent, MD, PhDCIMA, Universidad de NavarraCorreu electrònic verificat a unav.es
